Christophe Furman researcher
Furman, Christophe
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 318145541844696600039 (Personal)
Permalink: http://viaf.org/viaf/318145541844696600039
Preferred Forms
-
100 0 _
‡a
Christophe Furman
‡c
researcher
-
100 1 _
‡a
Furman, Christophe
4xx's: Alternate Name Forms (1)
Works
| Title | Sources |
|---|---|
| 6-Sulfonylbenzothiazolones as potential scaffolds for the design of 5-HT6 ligands |
|
| Antagonists of the adenosine A2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity. |
|
| Antagonists of the P2X7 receptor: mechanism of enantioselective recognition using highly sulfated and sulfobutylether cyclodextrins by capillary electrokinetic chromatography. |
|
| Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development |
|
| Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta |
|
| Development and validation of a reversed-phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers |
|
| Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. |
|
| Di-tert-butylhydroxylated flavonoids protect endothelial cells against oxidized LDL-induced cytotoxicity. |
|
| Differential toxicities of air (mO-LDL) or copper-oxidized LDLs (Cu-LDL) toward endothelial cells. |
|
| Enantioseparation of pyroglutamide derivatives on polysaccharide based chiral stationary phases by high-performance liquid chromatography and supercritical fluid chromatography: a comparative study. |
|
| Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage |
|
| Evaluation and comparison of three different separation techniques for analysis of retroamide enantiomers and their biological evaluation against h-P2X7 receptor |
|
| Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. |
|
| Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression |
|
| Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner |
|
| Ozonized low density lipoprotein (ozLDL) inhibits NF-kappaB and IRAK-1-associated signaling. |
|
| Part 2: discovery of new agonists endowed with protective effect against experimental colitis. |
|
| Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages |
|
| Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer. |
|
| Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease |
|
| REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophage cell death. |
|
| Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. |
|
| Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands |
|
| Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands |
|
| Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery |
|
| Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. |
|
| Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages |
|
| Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. |
|
